0
0
London, UK – A groundbreaking study utilizing deep learning has identified key genes associated with accelerated brain aging and potential drugs that could slow down this process. Published in Science Advances, the research analyzed MRI data from nearly 39,000 participants in the UK Biobank, revealing seven genes linked to a widening brain age gap (BAG) and 13 existing drugs that could target these genes.
The BAG, the difference between a person’s biological brain age and their chronological age, is a critical biomarker for brain health. A larger BAG is often associated with neurodegenerative diseases like Alzheimer’s and cognitive decline. Researchers aimed to pinpoint the genetic factors driving this aging process using advanced deep learning models.
By analyzing MRI scans, lifestyle data, health records, and genetic information, the scientists identified seven genes—MAPT, TNFSF12, GZMB, SIRPB1, GNLY, NMB, and C1RL—as promising targets for slowing brain aging. The 3D-ViT model, used in the study, accurately predicted participants’ biological brain age by analyzing key signatures in their MRI scans. Saliency map analysis highlighted the lentiform nucleus and the posterior limb of the internal capsule as crucial brain regions in this process.
Combining these genetic insights with existing clinical trial data, the researchers identified 13 drugs and supplements, including hydrocortisone, testosterone, diclofenac, and metformin, that could potentially be repurposed to slow brain aging.
“Slowing the aging process, especially in the brain, is a powerful strategy to prevent many diseases and enhance longevity,” said lead researcher [Researcher name would be added here if provided]. “Our findings provide a genetic basis for developing new drugs and repurposing existing ones to improve brain health.”
The potential impact of slowing brain aging is significant. Previous research suggests that even a 2% delay in aging could result in trillions of dollars in healthcare savings.
However, the researchers emphasized that the study was conducted on a specific population in the UK. Further research across diverse populations is needed to validate these findings and understand their broader applicability.
“While these results are promising, it’s crucial to conduct more studies to confirm these findings in diverse populations and to assess the safety and efficacy of these drugs for slowing brain aging,” added [Researcher name would be added here if provided].
The study’s findings offer a potential roadmap for developing interventions to combat age-related cognitive decline and improve overall brain health.
Disclaimer: This article is based on research findings and does not constitute medical advice. The information provided should not be used for diagnosing or treating any health conditions. Always consult with a qualified healthcare professional before making any decisions related to your health or treatment. The results of this study were obtained from a population of a specific region. More research needs to be conducted across diverse populations to evaluate the true extent of these findings.
